SynthesisNeurosurgical review2022
Association of histological subtype with risk of recurrence in craniopharyngioma patients: a systematic review and meta-analysis.
Synthesis in Neurosurgical review, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiation therapy for childhood-onset craniopharyngioma: systematic review and meta-analysis.Journal of neuro-oncology · 2025Pooled it
- Predicting early recurrence of craniopharyngioma using multi-omics radiomic modeling: a retrospective cohort study.Neurosurgical review · 2026Article
- History before diagnosis in adult-onset craniopharyngioma: associations with initial presentation and long-term prognosis: a retrospective cohort study of 151 patients.Journal of endocrinological investigation · 2026Article
- Lethally aggressive multiply recurrent adamantinomatous craniopharyngioma without histological malignancy: illustrative cases.Journal of neurosurgery. Case lessons · 2026Article
- The interdisciplinary management of craniopharyngioma - practice patterns, outcomes, and insights.BMC cancer · 2025Article
- Whole exome sequencing study of adamantinomatous craniopharyngioma reveals the mutational characteristics of recurrent cases.Journal of neuro-oncology · 2025Article
- Tumor features in adult papillary and adamantinomatous craniopharyngioma: neuroradiological evaluation of pituitary-hypothalamic-axis dysfunction and outcome prediction.Neuroradiology · 2025Article
- Isolation and Characterization of the Adamantinomatous Craniopharyngioma Primary Cells with Cancer-Associated Fibroblast Features.Biomedicines · 2025Article
- Individual management and prognostic assessment for long-term outcomes using a novel classification system of craniopharyngiomas: a retrospective study of single institution.Journal of cancer research and clinical oncology · 2025Article
- Factors influencing fear of disease recurrence in postoperative craniopharyngioma patients.American journal of translational research · 2025Article
- Long-term outcome of childhood and adolescent patients with craniopharyngiomas: a single center retrospective experience.BMC cancer · 2024Article
- Comparison of central diabetes insipidus (antidiuretic hormone deficiency) and stalk effect in patients with adamantinomatous and papillary craniopharyngioma.Acta neurologica Belgica · 2024Article
- Review
- Proteomics study of primary and recurrent adamantinomatous craniopharyngiomas.Clinical proteomics · 2024Article
- Development and validation of a prediction model for consistency of pituitary adenoma: the PiTCon score.Acta neurochirurgica · 2024Article
- Pearls & Oy-sters: Adult-Onset Craniopharyngioma Presenting With Cognitive Dysfunction and Obstructive Hydrocephalus.Neurology · 2023Article
- Article
- Predicting tumor consistency and extent of resection in non-functioning pituitary tumors.Pituitary · 2023Article
- Pathological Diagnosis of Adult Craniopharyngioma on MR Images: An Automated End-to-End Approach Based on Deep Neural Networks Requiring No Manual Segmentation.Journal of clinical medicine · 2022Article
- Current Advances in the Management of Adult Craniopharyngiomas.Current oncology (Toronto, Ont.) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
It is controversial whether there is a different risk of recurrence between two histological subtypes in craniopharyngioma (CP) patients. Some reported that adamantinomatous craniopharyngioma (ACP) had a higher risk of recurrence than papillary craniopharyngioma (PCP), but others reported that there is no significant difference between them. So, we conducted this systematic review and meta-analysis to determine the association between the histological subtype of CP and the rate of recurrence. A comprehensive literature search was undertaken in PubMed, EMBASE, and Web of Science for all English articles published up to November 2020. Recurrence data stratified by ACP and PCP were extracted from studies meeting inclusion criteria. A pooled analysis of the association between the histological subtype of craniopharyngioma and rates of recurrence was performed. Thirteen articles containing 974 patients were included. When stratified by two pathological subtypes, the total recurrence rate of ACP was 26.0% and PCP was 14.1%, which showed ACP associated with a higher risk of tumor recurrence than PCP (odds ratio [OR] = 2.12, 95% confidence interval [CI] = 1.36, 3.30, P = 0.00). This is the first meta-analysis focusing on histological subtypes of CP. PCP associates with a lower risk of recurrence than ACP, indicating that ACP could act as one of recurrence risk factors for CP patients. Nevertheless, large sample size and well-designed multicenter studies in which the other clinical variables are controlled to determine the histological subtype of CP as an independent recurrence risk factor are needed.
Indexed as
Identifiers
34159471What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.